Side-Stepping the Guardian of the Genome: Current Cancer Therapeutics Targeting Mutant p53

Abstract excerpt

Cancer therapies have attempted to target the transcription factor p53, a gene also described as the “guardian of the genome,” for decades. However, the approach has faced numerous barriers to clinical efficacy due to several factors: mutations in p53 occur in almost half of all human cancers, mutations are cancer-specific, and the associated genomic changes grant mutant p53 with oncogenic potential unique from th...

Topics

Open a Topic to create a Post that cites this publication.

• Apoptosis
• Cancer-related Molecular Pathways
• DNA Damage
• Genetic Therapy
• Molecular Targeted Therapy
• Mutation
• Neoplasms
• Tumor Suppressor Protein p53

Identifiers and source

Literature Corpus work

4b7e2d31-5bd4-5e2f-9109-461dc8848f60

DOI

10.22541/au.172777930.04032955/v1